2023 ESMO｜一文速览ADC药物相关内容

媒介

2023年欧洲肿瘤内科学会(ESMO)大会将于10月20日至24日（中欧夏令时间CEST)在西班牙马德里召开。作为全球最具影响力的肿瘤学会议之一，每年都受到世界各地浩瀚医疗行业从业者的配合存眷。

抗体偶联药物(ADC)作为一种新型的生物制剂，具有伟大的潜力和临床价格。本次ESMO大会上也发布了好多ADC药物的研究，整顿如下，让我们一睹为快！

(注：文中时间均为中欧夏令时间CEST，CEST=北京时间-6小时）

实体瘤篇

LBA

LBA34

德曲妥珠单抗(T-DXd)治疗经治的HER2表达实体瘤患者(pts)：DESTINY-PanTumor02(DP-02)研究的首要剖析究竟

Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: primary analysis from the DESTINY-PanTumor02 (DP-02) study.

讲者: Funda Meric-Bernstam(Houston, United States of America)

会议名称: Mini oral session - Developmental therapeutics(ID 268)

时间:2023年10月23日16:40-16:45

Oral或mini oral

656MO

针对HER2表达/突变晚期非乳腺癌实体瘤 (ST) 的HER2靶向ADC药物SHR-A1811：全球I期研究究竟

The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): results from the global phase 1 study.

讲者:Yiming Zhao(Guangzhou, China)

会议名称:Mini oral session - Developmental therapeutics(ID 268)

时间:2023年10月23日16:30-16:35

658MO

HER3靶向ADC药物SHR-A2009治疗晚期实体瘤的I期研究

Phase 1 study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors

讲者:Yi-Long Wu(Guangzhou, China)

会议名称:Mini oral session - Developmental therapeutics(ID 268)

时间:2023年10月23日16:40-16:45

654O

德曲妥珠单抗(T-DXd)在携带特异性HER2激活突变(HER2m)实体瘤患者中的疗效和平安性：全球II期DESTINY-PanTumor01 (DPT-01)研究的首要究竟

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): primary results from the international phase 2 DESTINY-PanTumor01 (DPT-01) study.

讲者:Bob T. Li(New York, United States of America)

会议名称:Proffered Paper session - Developmental therapeutics(ID 80)

时间:2023年10月22日09:20-09:30

657MO

首次人体免疫刺激抗体偶联物(ISAC)BDC-1001在HER2表达晚期实体瘤患者中的介绍2期剂量选择(RP2D)和药效动力学(PD)数据

Recommended phase 2 dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors

讲者:Bob T. Li(New York, United States of America)

会议名称:Mini oral session - Developmental therapeutics(ID 268)

时间:2023年10月23日16:35-16:40

659O

Nectin-4靶向ADC药物9MW2821治疗晚期实体瘤的I/II期临床研究初步究竟

Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting Nectin-4, in patients with advanced solid tumors

讲者:Jian Zhang(Shanghai, China)

会议名称:Mini oral session - Developmental therapeutics(ID 268)

时间:2023年10月23日17:20-17:25

660MO

SGN-B7H4V(一种B7-H4靶向vedotin ADC)在晚期实体瘤患者中的首次人体研究：I期研究 (SGNB7H4V-001) 的初步究竟

First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase 1 study (SGNB7H4V-001)

讲者:Cesar A. Perez(Fort Myers, United States of America)

会议名称:Mini oral session - Developmental therapeutics(ID 268)

时间:2023年10月23日17:25-17:30

上下滑动查察6项口头研究会议信息

Poster

148P

针对HER2表达实体瘤患者开展的德曲妥珠单抗(T-DXd) DESTINY-PanTumor02研究：组织和血浆中HER2表达和基因扩增的生物标记物索求性剖析

DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma

讲者：Vicky Makker(New York City, United States of America)

展示时间：2023年10月21日

375TiP

DS-1103a结合德曲妥珠单抗 (T-DXd) 用于晚期实体瘤患者的 I期、部门II期，首次人体多中心剂量递增和剂量扩增研究

A phase 1, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors

讲者：Ludimila Cavalcante(Atlanta, United States of America)

展示时间：2023年10月21日

438P

ZV0203(首创帕妥珠单抗ADC)针对HER2阳性晚期实体瘤患者的I期研究

Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+ advanced solid tumors

讲者：Fengjuan Lin(Shanghai, China)

展示时间：2023年10月21日

689P

DB-1305(Trop-2靶向抗体药物偶联物ADC)在晚期实体瘤患者(pts)中的应用：I/IIa期研究的初步临床究竟

DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) 1/2a study.

讲者：Omkar Marathe(Fountain Valley, United States of America)

展示时间：2023年10月23日

690P

Ifinatamab deruxtecan (I-DXd; DS-7300) 治疗晚期实体瘤患者：I/II期研究的最新临床数据和生物标记物究竟

Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: updated clinical and biomarker results from a phase 1/2 study

讲者：Manish R Patel(Fort Myers, United States of America)

展示时间：2023年10月23日

692P

在叶酸受体α(FRα)过表达实体瘤患者中应用ELU001(一种纳米粒子靶向药物偶联物)的首次人体试验

First-in-Human Study of ELU001, a Targeted Nanoparticle Drug Conjugate, in Subjects with Folate Receptor α (FRα) Overexpressing Solid Tumors.

讲者：Wen wee Ma(Sandusky, United States of America)

展示时间：2023年10月23日

2029TiP

SEZ6靶向抗体药物偶联物ABBV-706零丁或结合用于晚期实体瘤成人患者的I期研究

Phase 1 study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors

讲者：Sreenivasa Chandana(Grand Rapids, United States of America)

展示时间：2023年10月21日

上下滑动查察7项壁报研究会议信息

乳腺癌篇

LBA

LBA11

针对经治的无法手术或转移性激素受体阳性、HER2阴性(HR+/HER2-)乳腺癌(BC)患者，Datopotamab deruxtecan(Dato-DXd)与化疗的对照研究：TROPION-Breast01随机III期试验的初步究竟

Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised Phase 3 TROPION-Breast01 trial

讲者: Aditya Bardia (Boston, United States of America)

会议名称: Presidential 3 (ID 156)

时间:2023年10月23日16:30-16:42

Oral或mini oral

376O

德曲妥珠单抗(T-DXd)与大夫选择疗法(TPC)治疗HER2低表达弗成切除和/或转移性乳腺癌(mBC)患者(pts)：随机III期DESTINY-Breast04研究的最新生存究竟

Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): UpDate:d survival results of the randomized, phase 3 DESTINY-Breast04 study

讲者:Shanu Modi (New York, United States of America)

会议名称:Proffered Paper session - Breast cancer, metastatic (ID 40)

时间:2023年10月21日10:25-10:35

377O

DESTINY-Breast(DB)01研究、DB02和DB03研究中德曲妥珠单抗(T-DXd)对HER2阳性(HER2+)转移性乳腺癌(mBC)伴脑转移(BMs)患者(pts)疗效的汇总剖析。

A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03.

讲者:Sara A. Hurvitz (Santa Monica, United States of America)

会议名称:Proffered Paper session - Breast cancer, metastatic (ID 40)

时间:2023年10月21日10:55-11:05

379MO

Datopotamab deruxtecan (Dato-DXd) + 度伐利尤单抗 (D) 用于弗成切除的局部晚期/转移性三阴性乳腺癌 (a/mTNBC) 的一线 (1L) 治疗：Ib/II期BEGONIA研究的最新究竟

Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study.

讲者:Peter Schmid (London, United Kingdom)

会议名称: Mini oral session - Breast cancer, metastatic (ID 77)

时间:2023年10月22日08:30 - 08:35

380MO

SKB264(MK-2870)用于经治的转移性激素受体阳性(HR+)和HER2阴性乳腺癌患者的I/II期单臂篮子试验

SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial

讲者:Yongmei Yin (Nanjing, China)

会议名称:Mini oral session - Breast cancer, metastatic (ID 77)

时间:2023年10月22日08:35-08:40

381O

靶向B7-H4的ADC药物HS-20089，用于晚期实体瘤患者的首次人体试验/I期试验

First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors

讲者:Jian Zhang (Shanghai, China)

会议名称:Proffered Paper session - Breast cancer, metastatic (ID 40)

时间:2023年10月21日10:15-10:25

385MO

一项DP303c用于经治HER2阳性晚期实体瘤患者的多中心、开放标签、剂量递增和扩展研究

A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors

讲者:Yiqun Du (Shanghai, China)

会议名称:Mini oral session - Breast cancer, metastatic (ID 77)

时间:2023年10月22日09:30-09:35

386MO

Trastuzumab duocarmazine与大夫选择疗法治疗既往接管过治疗的HER2阳性转移性乳腺癌：III期TULIP试验的最终究竟

Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial.

讲者:Philippe G. Aftimos (Anderlecht, Belgium)

会议名称:Mini oral session - Breast cancer, metastatic (ID 77)

时间:2023年10月22日09:35-09:40

上下滑动查察7项口头研究会议信息

Poster

33P

在纳米水平上可视化德曲妥珠单抗对HER2阳性乳腺癌细胞的感化

Visualizing Trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale

讲者：Katia Cortese (Genova, Italy)

展示时间：2023年10月22日

388P

对照德曲妥珠单抗 (T-DXd) 与大夫选择疗法 (TPC) 的随机III期研究——DESTINY-Breast04研究中基线伴脑转移 (BM) 的HER2低表达转移性乳腺癌 (mBC) 患者的亚组剖析

Subgroup Analysis of Patients (pts) With HER2-Low Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) at Baseline From DESTINY-Breast04, a Randomized Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) vs Treatment of Physician’s Choice (TPC)

讲者：Junji Tsurutani (Shinagawa-ku, Japan)

展示时间：2023年10月21日

389P

在HR+/HER2-转移性乳腺癌(mBC)患者(pts)中开展的对比戈沙妥珠单抗(SG)与大夫选择疗法(TPC)的III期TROPiCS-02研究中，按既往化疗线数进行的疗效和平安性剖析

Efficacy and safety analyses by prior lines of chemotherapy from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC).

讲者：Javier Cortés (Madrid, Spain)

展示时间：2023年10月21日

397P

重组人源化HER2靶向单抗MMAE偶联物RC48-ADC在HER2阳性或HER2低表达的局部晚期或转移性乳腺癌患者中疗效和平安性：单臂II期研究

Efficacy and safety of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive or HER2-low expressing, locally advanced or metastatic breast cancer: a single-arm phase II study

讲者：Fei Qu (Nanjing, China)

展示时间：2023年10月21日

412P

戈沙妥珠单抗对比化疗治疗转移性乳腺癌的平安性调集剖析

Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes.

讲者：Alessandro Rizzo (Bologna, Italy)

展示时间：2023年10月21日

414P

德曲妥珠单抗治疗HER2阳性乳腺癌脑转移：系统综述与Meta剖析

Trastuzumab Deruxtecan for HER2-positive Breast Cancer Brain Metastasis: a Systematic Review and Meta-analysis

讲者：Isabella F. Michelon (Pelotas, Brazil)

展示时间：2023年10月21日

685P

HER2靶向抗体药物偶联物BL-M07D1用于局部晚期或转移性HER2表达乳腺癌和其他实体瘤患者的应用研究

BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors

讲者：Erwei Song (Guangzhou, China)

展示时间：2023年10月23日

上下滑动查察7项壁报研究会议信息

肺癌篇

LBA

LBA12

对于经治的晚期/转移性(adv/met)非小细胞肺癌(NSCLC)进行Datopotamab deruxtecan(Dato-DXd)与多西他赛的对比研究：TROPION-Lung 01随机III期研究的究竟

Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase 3 study TROPION-Lung 01

讲者: Aaron E. Lisberg (Los Angeles, United States of America)

会议名称: Presidential 3 (ID 156)

时间:2023年10月23日16:42-16:54

Oral或mini oral

655O

Cofetuzumab Pelidotin (一种靶向PTK7的抗体药物偶联物) 在表达PTK7的复发性非小细胞肺癌 (rNSCLC) 患者中的1b期研究

Phase 1b Study of Cofetuzumab Pelidotin, an Anti-PTK7 Antibody-Drug Conjugate, in Patients with PTK7-Expressing Recurrent Non-Small Cell Lung Cancer (rNSCLC).

讲者: Byoung Chul Cho (Seoul, Korea, Republic of)

会议名称: Proffered Paper session - Developmental therapeutics (ID 80)

时间:2023年10月22日09:30-09:40

1314MO

TROPION-Lung05：Datopotamab deruxtecan (Dato-DXd) 治疗既往经治的携带可靶向基因组改变 (AGA) 的非小细胞肺癌 (NSCLC) 患者

TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs).

讲者: Luis Paz-Ares (Madrid, Spain)

会议名称:Mini oral session 1 - NSCLC, metastatic (ID 35)

时间:2023年10月21日09:30-09:35

1316MO

BL-B01D1是一种首创的EGFRxHER3双特异性抗体药物偶联物，用于治疗非小细胞肺癌患者：首次人体 I 期研究的更新究竟

BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Non-Small Cell Lung Cancer: Updated results from first-in-human phase 1 study.

讲者: Li Zhang (Guangzhou, China)

会议名称:Mini oral session 1 - NSCLC, metastatic (ID 35)

时间:2023年10月21日09:40-09:45

1318MO

ABBV-637 (一种靶向EGFR的BCL-XL-按捺抗体药物偶联物) 结合奥希替尼 (OSI) 治疗复发性/难治性EGFR突变非小细胞肺癌 (NSCLC) 的首次人体研究

First-in-Human Study of ABBV-637, an EGFR-targeting BCL-XL–Inhibiting Antibody-Drug Conjugate Combined With Osimertinib (OSI) in Relapsed/Refractory, EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC).

讲者: Julia K. Rotow (Boston, United States of America)

会议名称:Mini oral session 2 - NSCLC, metastatic (ID 114)

时间:2023年10月22日16:45-16:50

1319MO

HER3-DXd对经治晚期EGFR突变非小细胞肺癌 (NSCLC) 患者的颅内疗效：来自HERTHENA-Lung01研究的究竟

Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: results from HERTHENA-Lung01.

讲者: Melissa L. Johnson (Nashville, United States of America)

会议名称:Mini oral session 2 - NSCLC, metastatic (ID 114)

时间:2023年10月22日17:05-17:10

1321MO

德曲妥珠单抗 (T-DXd) 治疗伴或不伴脑转移 (BMs) 的HER2 (ERBB2) 突变 (HER2m) 转移性非小细胞肺癌 (NSCLC) 患者(pts)：DESTINY-Lung01研究和DESTINY-Lung02研究的汇总剖析

Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2 (ERBB2)-Mutant (HER2m) Metastatic Non–Small Cell Lung Cancer (NSCLC) With and Without Brain Metastases (BMs): Pooled Analyses From DESTINY-Lung01 and DESTINY-Lung02.

讲者: David Planchard (Villejuif, Cedex, France)

会议名称:Mini oral session 2 - NSCLC, metastatic (ID 114)

时间:2023年10月22日17:10-17:15

1990MO

戈沙妥珠单抗 (SG) 用于普遍期小细胞肺癌 (ES-SCLC) 的二线 (2L) 治疗：II期TROPiCS-03篮子试验的初步究竟

Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase 2 TROPiCS-03 basket trial.

讲者:Afshin Dowlati (Cleveland, United States of America)

会议名称:Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies (ID 60)

时间:2023年10月21日14:55-15:00

上下滑动查察7项口头研究会议信息

Poster

151P

德曲妥珠单抗 (T-DXd) 治疗人表皮生长因子受体 2 (HER2) 过表达转移性非小细胞肺癌 (NSCLC) 患者的基线轮回肿瘤DNA (ctDNA) 生物标记物剖析

Baseline Circulating Tumor DNA (ctDNA) Biomarker Analysis of Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Non–Small Cell Lung Cancer (NSCLC) Treated With Trastuzumab Deruxtecan (T-DXd).

讲者: Egbert F. Smit（Leiden, Netherlands）

展示时间:2023年10月21日

1411P

Tusamitamab ravtansine结合ramucirumab方案用于CEACAM5高表达 (CARMEN-LC04) 的转移性NSq NSCLC患者的2线及今后治疗的研究

Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04).

讲者: Grace K. Dy (Buffalo, United States of America)

展示时间:2023年10月23日

1419P

TACSTD2 (Trop-2) 是治疗非小细胞肺癌脑转移患者的极具前景的抗体药物偶联物的靶点

TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases.

讲者: Sara Hijazo-Pechero (Hospitalet de Llobregat, Spain)

展示时间:2023年10月23日

1505TiP

TROPION-Lung07研究：一项datopotamab deruxtecan (Dato-DXd) + 帕博利珠单抗 (pembro) 结合或不结合铂类化疗（Pt-CT）作为PD-L1表达晚期/转移性 (adv/met) 非小细胞肺癌 (NSCLC) 一线 (1L) 治疗的III期试验

TROPION-Lung07: A phase 3 trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression.

讲者: Isamu Okamoto (Fukuoka, Japan)

展示时间:2023年10月23日

1507TiP

德曲妥珠单抗 (T-DXd) 和免疫疗法结合或不结合化疗用于HER2过表达 (OE) 晚期或转移性非鳞状非小细胞肺癌 (NSCLC) 患者 (pts) 的Ib期多中心研究：DESTINY-Lung03研究

Phase 1b multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03.

讲者: David Planchard (Villejuif, Cedex, France)

展示时间:2023年10月23日

上下滑动查察5项壁报研究会议信息

妇科肿瘤篇

LBA

LBA9

innovaTV 301/ENGOT-cx12/GOGG-3057研究：一项对比Tisotumab Vedotin与研究者选择化疗方案针对2L或3L复发性或转移性宫颈癌的全球性、随机、开放标签III期研究

innovaTV 301/ENGOT-cx12/GOG-3057: A Global, Randomized, Open-Label, Phase 3 Study of Tisotumab Vedotin vs Investigator’s Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer.

讲者: Ignace B. Vergote (Leuven, Belgium)

会议名称: Presidential 2 (ID 112)

时间:2023年10月22日17:22-17:34

Oral或mini oral

741MO

抗叶酸受体α (FolRα) 抗体药物偶联物 (ADC) Luveltamab Tazevibulin (STRO-002) 在复发性/进展性上皮性质宫内膜癌 (EEC) 中显露出临床活性：STRO-002-GM1 I期剂量扩展研究

Luveltamab Tazevibulin (STRO-002), an anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate (ADC), Demonstrates Clinical Activity in Recurrent/Progressive Epithelial Endometrial Cancer (EEC): STRO-002-GM1 Phase 1 Dose Expansion.

讲者: Bhavana Pothuri (New York, United States of America)

会议名称: Mini oral session - Gynaecological cancers (ID 90)

时间:2023年10月22日10:25-10:30

745MO

Raludotatug deruxtecan (R-DXd；DS-6000) 单药治疗既往经治卵巢癌 (OVC) 患者：首次人体I期研究的亚组剖析

Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase 1 study.

讲者: Kathleen N. Moore (Oklahoma City, United States of America)

会议名称:Mini oral session - Gynaecological cancers (ID 90)

时间:2023年10月23日08:30-08:35

上下滑动查察2项口头研究会议信息

Poster

777P

靶向上皮性卵巢癌中Cadherin-6：Raludotatug Deruxtecan (R-DXd) 在患者衍生细胞模型中的临床意义和疗效

Targeting Cadherin-6 in Epithelial Ovarian Cancer: Clinical Significance of its Expression and Efficacy of Raludotatug Deruxtecan（R-DXd）in Patient-Derived Cell Models.

讲者: Daisuke Shintani (Saitama, Japan)

展示时间:2023年10月22日

818TiP

REFRaME-O1/ENGOT-OV79/GOG-3086研究: 一项对比Luveltamab Tazevibulin与研究者选择化疗在叶酸受体α (FolRα) 表达的复发性铂类耐药上皮性卵巢癌女性患者中疗效和平安性的II/III期开放标签研究

REFRaME-O1/ENGOT-OV79/GOG-3086: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin versus Investigator’s Choice of Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer Expressing Folate Receptor alpha (FolRα).

讲者: R. Wendel Naumann (Concord, United States of America)

展示时间:2023年10月22日

上下滑动查察2项壁报研究会议信息

头颈癌篇

Oral或mini oral

859MO

Sacituzumab govitecan (SG) 治疗复发性/难治性 (R/R) 晚期头颈部鳞状细胞癌 (HNSCC) 患者：II期TROPiCS-03篮子试验的究竟

Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase 2 TROPiCS-03 basket trial.

讲者: Loren Michel (New York, United States of America)

会议名称: Mini oral session - Head and neck cancer (ID 45)

时间:2023年10月21日11:10-11:15

860MO

MRG003，一种用于复发性/转移性鼻咽癌的新型EGFR靶向抗体药物偶联物 (ADC)

MRG003, a novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic Nasopharyngeal Carcinoma.

讲者: Fei Han (Guangzhou, China)

会议名称:Mini oral session - Head and neck cancer (ID 45)

时间:2023年10月21日11:15-11:20

上下滑动查察2项口头研究会议信息

Poster

939P

新型EGFR靶向ADC药物MRG003在复发性或转移性头颈部鳞状细胞癌患者中的疗效和平安性

Efficacy and Safety of a Novel Anti-EGFR ADC MRG003 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck patients.

讲者: Liqiong Xue (Shanghai, China)

展示时间:2023年10月22日

泌尿肿瘤篇

LBA

LBA6

EV-302/KEYNOTE-A39研究：Enfortumab Vedotin结合帕博利珠单抗(EV+P)与化疗(Chemo)治疗既往未经治疗的局部晚期转移性尿路上皮癌(la/mUC)的开放标签、随机III期研究

EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC).

讲者: Thomas B. Powles(London, United Kingdom)

会议名称:Presidential 2(ID 112)

时间:2023年10月22日16:30-16:42

Oral或mini oral

2360MO

双抗体药物偶联物 (DAD)的I期试验：Sacituzumab govitecan(SG) + enfortumab vedotin(EV) 作为转移性尿路上皮癌 (mUC) 的≥2线治疗

The Double Antibody Drug conjugate (DAD) Phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ Second line therapy for metastatic urothelial carcinoma (mUC).

讲者: Bradley A. McGregor(Boston, United States of America)

会议名称:Proffered Paper session 1 - Genitourinary tumours, non-prostate(ID 27)

时间:2023年10月22日10:15-10:20

Poster

41P

用于前列腺癌治疗的新一代PSMA靶向抗体药物偶联物ARX517在恩扎卢胺耐药和恩扎卢胺敏感的药理学模型以及毒理学模型中进行的临床前评估

Evaluation of ARX517, a next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models.

讲者：Shawn Zhang(La Jolla, United States of America)

展示时间：2023年10月22日

1804P

APEX-01研究：前列腺特异性膜抗原(PSMA)靶向抗体药物偶联物(ADC)ARX517在转移性去势抗击性前列腺癌(mCRPC)患者(pts)中的首次人体I/II期研究

APEX-01: First-in-human phase 1/2 study of ARX517, an anti-prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

讲者：John Shen(Los Angeles, United States of America)

展示时间：2023年10月22日

1842TiP

两种剂量水平的Vobramitamab Duocarmazine用于转移性去势抗击性前列腺癌 (mCRPC; TAMARACK) 患者的II期随机试验

Phase 2 Randomized Trial of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC; TAMARACK).

讲者： Johann S. De Bono(Sutton, United Kingdom)

展示时间：2023年10月22日

上下滑动查察3项壁报研究会议信息

其他癌种篇(仅Poster)

1171P

黑色素瘤中抗体药物偶联物 (ADC) 和PD-L1的肿瘤相关抗原 (TAAs) 的转录组评估：新的临床时机选择

Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: options for new clinical opportunities.

讲者：Jorge Bartolome(Madrid, Spain)

展示时间：2023年10月22日

1574P

德曲妥珠单抗对比雷莫西尤单抗+紫杉醇用于HER2阳性胃癌或胃食管接壤处腺癌患者的二线治疗：倾向评分成家法对照研究

Trastuzumab Deruxtecan versus Ramucirumab and Paclitaxel as second-line therapy for patients with HER2-positive gastric or gastro-esophageal junction adenocarcinoma: a propensity score matched comparison.

讲者：Rob H. Verhoeven(Utrecht, Netherlands)

展示时间：2023年10月23日

上下滑动查察2项壁报研究会议信息

其他ADC药物进展篇(仅Poster)

71P

用于治疗CD70表达肿瘤的新一代CD70靶向抗体药物偶联物ARX305的临床前特征研究

Preclinical characterization of ARX305, a next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers.

讲者：Lillian Skidmore(La Jolla, United States of America)

展示时间：2023年10月22日

683P

EGFR靶向ADC药物HLX42用于西妥昔单抗或TKI耐药肿瘤的临床前评估

Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer

讲者：Yongqiang Shan(Shanghai, China)

展示时间：2023年10月23日

693P

PD-L1靶向ADC药物HLX43在多种PD-1/PD-L1难治/耐药模型中的临床前活性

Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models.

讲者：Yongqiang Shan(Shanghai, China)

展示时间：2023年10月23日

756P

新型Claudin 6 (CLDN6) 靶向抗体药物偶联物 (ADC) TORL-1-23 的首次人体I期研究

First-in-Human Phase 1 Study of a Novel Claudin 6 (CLDN6) targeted Antibody Drug Conjugate (ADC) TORL-1-23.

讲者：Gottfried E. Konecny(Los Angeles, United States of America)

展示时间：2023年10月22日

1828P

新一代PSMA靶向抗体药物偶联物(ADC)ARX517在ARX517 I期临床试验(APEX-01)中显现出显著的不乱性和药代动力学(PK)特征

ARX517, a next generation anti-PSMA antibody drug conjugate (ADC), demonstrates notable stability and pharmacokinetic (PK) profile in the ARX517 phase 1 clinical trial (APEX-01).

讲者：Scott T. Tagawa(New York, United States of America)

展示时间：2023年10月22日

2090P

德曲妥珠单抗相关恶心和吐逆在真实世界的应对方式

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.

讲者： Luca Licata(Milan, Italy)

展示时间：2023年10月21日

2155P

首次间质性肺病/肺炎(ILD/p)康复后德曲妥珠单抗(T-DXd)再治疗的结果

Outcomes With Trastuzumab Deruxtecan (T-DXd) Retreatment After Recovery From First Interstitial Lung Disease/Pneumonitis (ILD/p).

讲者：Hope S. Rugo(San Francisco, United States of America)

展示时间：2023年10月21日